In the last trading session, 1.3 million shares of the Cardiff Oncology Inc (NASDAQ:CRDF) were traded, and its beta was 1.65. Most recently the company’s share price was $3.73, and it changed around -$0.09 or -2.10% from the last close, which brings the market valuation of the company to $248.47M. CRDF currently trades at a discount to its 52-week high of $6.42, offering almost -72.12% off that amount. The share price’s 52-week low was $2.01, which indicates that the current value has risen by an impressive 46.11% since then.
Cardiff Oncology Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 6 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 0 recommended CRDF as a Hold, whereas 4 deemed it a Buy, and 0 rated it as Underweight. Cardiff Oncology Inc is expected to report earnings per share of -0.2 for the current quarter.
Cardiff Oncology Inc (NASDAQ:CRDF) trade information
Instantly CRDF has showed a red trend with a performance of -2.10% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 4.55 on recent trading dayincreased the stock’s daily price by 18.02%. The company’s shares are currently down -13.94% year-to-date, but still down -11.70% over the last five days. On the other hand, Cardiff Oncology Inc (NASDAQ:CRDF) is -7.32% down in the 30-day period.
Cardiff Oncology Inc (CRDF) estimates and forecasts
The year-over-year growth rate is expected to be -51.20%, down from the previous year.
Consensus estimates provided by 6 financial analysts predict the company will bring in an average of 87.5k in revenue for the current quarter. 6 analysts expect Cardiff Oncology Inc to make 87.5k in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 205k and 163k respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -57.32%. Forecasts for the next quarter put sales growth at -46.32%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 19.36%. Cardiff Oncology Inc earnings are expected to increase by 16.14% in 2025, but the outlook is negative -7.72% per year for the next five years.
CRDF Dividends
Cardiff Oncology Inc’s next quarterly earnings report is expected to be released in April.
VANGUARD GROUP INC, with 4.7816% or 2.14 million shares worth $4.74 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF were the top two Mutual Funds as of Sep 30, 2024 . The former held 1.25 shares worth $4.69 million, making up 1.89% of all outstanding shares. On the other hand, iShares Russell 2000 ETF held roughly 1.08 shares worth around $4.04 million, which represents about 1.62% of the total shares outstanding.
